Basic Information
| LncRNA/CircRNA Name | SNHG1 |
| Synonyms | SNHG1, LINC00057, NCRNA00057, U22HG, UHG, lncRNA16 |
| Region | GRCh38_11:62851988-62855914 |
| Ensemble | ENSG00000255717 |
| Refseq | NR_003098 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, RNAi, Western blot, Luciferase reporter assay, Cell proliferation assay etc. |
| Sample | NSCLC tissues, cell lines (A549, SPC-A1, H23 and NCI-H520) |
| Expression Pattern | up-regulated |
| Function Description | SNHG1 was up-regulated in non-small cell lung cancer (NSCLC) tissues and cell lines. Furthermore,SNHG1 inhibition suppressed NSCLC cell proliferation both in vitro and in vivo. We also found that miR-101-3p could act as a target of SNHG1 in NSCLC and the inhibition of NSCLC progression induced by SNHG1 knockdown required the activity of miR-101-3p.In addition,we identified that SOX9 acted as a target of miR-101-3p,and SOX9 played the oncogenic role in NSCLC by activating Wnt/B-catenin signaling pathway. |
| Pubmed ID | 28147312 |
| Year | 2017 |
| Title | Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/B-catenin signaling pathway. |
External Links
| Links for SNHG1 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |